{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:55:59Z","timestamp":1792065359079,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xphs.2026.104532","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:09:42Z","timestamp":1791414582000},"page":"104532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Composition-dependent changes in the crystallization mechanism in drug\u2013drug coamorphous systems of related neuropeptide Y Y5 receptor antagonists"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3061-2596","authenticated-orcid":false,"given":"Hiroshi","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-3631","authenticated-orcid":false,"given":"Hironori","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1103-7060","authenticated-orcid":false,"given":"Yuna","family":"Shimazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3123-681X","authenticated-orcid":false,"given":"Shohei","family":"Aikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.xphs.2024.08.029","article-title":"Amorphous solubility advantage: theoretical considerations, experimental methods, and contemporary relevance","volume":"114","author":"Ueda","year":"2025","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104532_bib0002","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.powtec.2015.05.012","article-title":"Amorphous formulations for dissolution and bioavailability enhancement of poorly soluble APIs","volume":"285","author":"Kanaujia","year":"2015","journal-title":"Powder Technol"},{"key":"10.1016\/j.xphs.2026.104532_bib0003","article-title":"A review on stabilization mechanism of amorphous form based drug delivery system","volume":"37","author":"Dhaval","year":"2023","journal-title":"Mater Today Commun"},{"issue":"6","key":"10.1016\/j.xphs.2026.104532_bib0004","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/mp400679m","article-title":"Relationship between crystallization tendencies during cooling from melt and isothermal storage: toward a general understanding of physical stability of pharmaceutical glasses","volume":"11","author":"Kawakami","year":"2014","journal-title":"Mol Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2026.104532_bib0005","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jps.20298","article-title":"Calorimetric investigation of the structural relaxation of amorphous materials: evaluating validity of the methodologies","volume":"94","author":"Kawakami","year":"2005","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104532_bib0006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/jps.10582","article-title":"Evaluation of glassy-state dynamics from the width of the glass transition: results from theoretical simulation of differential scanning calorimetry and comparisons with experiment","volume":"93","author":"Pikal","year":"2004","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0007","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40199-026-00594-1","article-title":"Amorphous solid dispersions as a strategy to enhance the bioavailability and stability of formulations containing plant active ingredients: an integrative review","volume":"34","author":"de Oliveira Cardoso Melo","year":"2026","journal-title":"Daru"},{"key":"10.1016\/j.xphs.2026.104532_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125541","article-title":"A review on design rules for formulating amorphous solid dispersions based on drug-polymer interactions in aqueous environment","volume":"675","author":"Ramachandran","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104532_bib0009","article-title":"Trends in amorphous solid dispersion drug products approved by the U.S. food and drug administration between 2012 and 2023","volume":"7","author":"Moseson","year":"2024","journal-title":"Int J Pharm X"},{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.apsb.2018.08.002","article-title":"Advances in coamorphous drug delivery systems","volume":"9","author":"Shi","year":"2019","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"10.1016\/j.xphs.2026.104532_bib0011","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1208\/s12249-022-02421-7","article-title":"Co-amorphous drug delivery systems: a review of physical stability, in vitro and in vivo performance","volume":"23","author":"Shi","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2026.104532_bib0012","article-title":"Co-amorphous systems in drug delivery: mechanistic insights, stability challenges, and future perspectives","volume":"120","author":"Srividya","year":"2026","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104532_bib0013","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijpharm.2016.10.043","article-title":"Co amorphous systems: a product development perspective","volume":"515","author":"Chavan","year":"2016","journal-title":"Int J Pharm"},{"issue":"B","key":"10.1016\/j.xphs.2026.104532_bib0014","article-title":"Coamorphous systems of rebamipide: selection of amino acid coformers based on protein-ligand docking, in vitro assessment and study of interactions by computational and multivariate analysis","volume":"667","author":"Sharma","year":"2024","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2026.104532_bib0015","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1021\/acs.molpharmaceut.8b00174","article-title":"Application of a salt coformer in a co-amorphous drug system dramatically enhances the glass transition temperature: a case study of the ternary system carbamazepine, citric acid, and l-arginine","volume":"15","author":"Ueda","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104532_bib0016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpb.2018.07.016","article-title":"Organic acids as co-formers for co-amorphous systems\u2014influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems","volume":"131","author":"Wu","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104532_bib0017","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1021\/acs.molpharmaceut.2c00057","article-title":"Design of a stable coamorphous system using lactose as an antiplasticizing agent for diphenhydramine hydrochloride with a low glass transition temperature","volume":"19","author":"Ueda","year":"2022","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2026.104532_bib0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/pharmaceutics10030149","article-title":"Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors","volume":"10","author":"An","year":"2018","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.xphs.2026.104532_bib0019","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1021\/acs.molpharmaceut.0c01096","article-title":"Role of hydrogen bonds in formation of co-amorphous valsartan\/nicotinamide compositions of high solubility and durability with anti-hypertension and anti-COVID-19 potential","volume":"18","author":"Turek","year":"2021","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104532_bib0020","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1039\/D4PM00250D","article-title":"Formation of drug-drug salt crystals and co-amorphous forms of levofloxacin and 4-aminosalicylic acid for pulmonary applications","volume":"2","author":"Ueda","year":"2025","journal-title":"RSC Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0021","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/pharmaceutics15010196","article-title":"Eutectic mixture formation and relaxation dynamics of coamorphous mixtures of two benzodiazepine drugs","volume":"15","author":"Valenti","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0022","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.xphs.2016.07.009","article-title":"Co-amorphous formation induced by combination of tranilast and diphenhydramine hydrochloride","volume":"106","author":"Ueda","year":"2017","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2026.104532_bib0023","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1016\/j.xphs.2019.09.013","volume":"108","author":"Chieng","year":"2019","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2026.104532_bib0024","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/pharmaceutics11120628","article-title":"Determination of stable co-amorphous drug-drug ratios from the eutectic behavior of crystalline physical mixtures","volume":"11","author":"Kissi","year":"2019","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.xphs.2026.104532_bib0025","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/molecules26040801","article-title":"A multivariate approach for the determination of the optimal mixing ratio of the non-strong interacting co-amorphous system carvedilol-tryptophan","volume":"26","author":"Di","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.xphs.2026.104532_bib0026","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/acs.molpharmaceut.0c00042","article-title":"Determination of the optimal molar ratio in amino acid-based coamorphous systems","volume":"17","author":"Liu","year":"2020","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0027","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-82524-2","article-title":"A drug-drug co-amorphous system for highly improved solubility of breviscapine: an experimental and computational study","volume":"14","author":"Dong","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.xphs.2026.104532_bib0028","article-title":"A drug-drug co-amorphous formulation for enhanced solubility and transdermal absorption of rotundine","volume":"11","author":"Chen","year":"2026","journal-title":"Int J Pharm X"},{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0029","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/pharmaceutics15010084","article-title":"Formation of a stable co-amorphous system for a brick dust molecule by utilizing sodium taurocholate with high glass transition temperature","volume":"15","author":"Aikawa","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xphs.2026.104532_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114395","article-title":"Specific intermolecular interaction with sodium glycocholate generates the co-amorphous system showing higher physical stability and aqueous solubility of Y5 receptor antagonist of neuropeptide Y, a brick dust molecule","volume":"202","author":"Aikawa","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"issue":"9","key":"10.1016\/j.xphs.2026.104532_bib0031","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1016\/j.xphs.2023.04.012","article-title":"Formation of hemihydrate crystal form overcomes milling issue induced by exposed functional groups on cleavage plane for a Y5 receptor antagonist of neuropeptide Y","volume":"112","author":"Nagamatsu","year":"2023","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2026.104532_bib0032","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1021\/acs.cgd.5c01534","article-title":"Discovery of a new polymorph, \u03ba-form of indomethacin","volume":"26","author":"Shimazaki","year":"2026","journal-title":"Cryst Growth Des"},{"issue":"6","key":"10.1016\/j.xphs.2026.104532_bib0033","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3390\/pharmaceutics15061689","article-title":"Application of TGA\/c-DTA for distinguishing between two forms of naproxen in pharmaceutical preparations","volume":"15","author":"Ramos","year":"2023","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.xphs.2026.104532_bib0034","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1021\/acs.molpharmaceut.3c00756","article-title":"Improvement in inhalation properties of theophylline and levofloxacin by co-amorphization and enhancement in its stability by addition of amino acid as a third component","volume":"20","author":"Ueda","year":"2023","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1016\/j.xphs.2026.104532_bib0035","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1021\/acs.molpharmaceut.5c01164","article-title":"Eutectic coamorphous system of enzalutamide and acetyl maltose: a strategy for improved physical stability and aqueous solubility","volume":"23","author":"Cichocka-\u0141okuciejewska","year":"2026","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2026.104532_bib0036","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/molecules22020296","article-title":"Amorphous-amorphous phase separation in API\/polymer formulations","volume":"22","author":"Luebbert","year":"2017","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.xphs.2026.104532_bib0037","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s11095-015-1848-2","article-title":"A strategy for co-former selection to design stable co-amorphous formations based on physicochemical properties of non-steroidal inflammatory drugs","volume":"33","author":"Ueda","year":"2016","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.xphs.2026.104532_bib0038","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.9b00105","article-title":"Application of co-amorphous technology for improving the physicochemical properties of amorphous formulations","volume":"16","author":"Mizoguchi","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.xphs.2026.104532_bib0039","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2023.01.019","article-title":"Mechanistic insights into the crystallization of coamorphous drug systems","volume":"354","author":"Heng","year":"2023","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.xphs.2026.104532_bib0040","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1021\/acs.molpharmaceut.5c00700","article-title":"Nucleation in amorphous terfenadine at a temperature much lower than the glass transition temperature and its impact on physical stability","volume":"22","author":"Yamaguchi","year":"2025","journal-title":"Mol Pharm"},{"issue":"7","key":"10.1016\/j.xphs.2026.104532_bib0041","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1021\/acs.jpcb.4c07005","article-title":"Crystal nucleation in ibuprofen glass: possible relevance between the characteristic length of the cooperatively rearranging region and the size of crystal nuclei","volume":"129","author":"Kawakami","year":"2025","journal-title":"J Phys Chem B"},{"issue":"1","key":"10.1016\/j.xphs.2026.104532_bib0042","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.xphs.2024.06.012","article-title":"Efficient determination of critical water activity and classification of hydrate-anhydrate stability relationship","volume":"114","author":"Yao","year":"2025","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:29:26Z","timestamp":1792063766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0022354926003825"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104532","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composition-dependent changes in the crystallization mechanism in drug\u2013drug coamorphous systems of related neuropeptide Y Y5 receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104532","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104532"}}